Loading
Veraxa Biotech AG is a clinical-stage biopharmaceutical company specializing in next-generation antibody-based cancer therapies. [9] The company is advancing a drug discovery and development engine for ADCs and other novel antibody-based therapy concepts. [14] It was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL). [8, 14]
Previous close
$0.0311
−$0.0018 · -5.47%
Regular session · ET · Market data may be delayed.
Veraxa Biotech AG is a clinical-stage biopharmaceutical company specializing in next-generation antibody-based cancer therapies. [9] The company is advancing a drug discovery and development engine for ADCs and other novel antibody-based therapy concepts. [14] It was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL). [8, 14]
Day range
Current $0.0311
52-week range
Current $0.0311
Regular session · ET · Market data may be delayed.
Veraxa Biotech AG is a clinical-stage biopharmaceutical company specializing in next-generation antibody-based cancer therapies. [9] The company is advancing a drug discovery and development engine for ADCs and other novel antibody-based therapy concepts. [14] It was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL). [8, 14]
Day range
Current $0.0311
52-week range
Current $0.0311
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
